Keros Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Pontifax Parties sold their entire stake of 4.79 million Keros Therapeutics shares back to the company for $84.98 million, leading to board resignations.
NASDAQ
Keros Therapeutics, Inc. has entered into a stock purchase agreement to repurchase 5,389,264 shares of its common stock from ADAR1 Capital Management and its affiliates for $95,659,436, as part of its previously announced $375 million Capital Return Program.
NASDAQ
ADAR1 Capital Management, Keros Therapeutics' largest stockholder, is pressing the Board for engagement on strategy, capital allocation, and board refreshment, threatening a proxy fight.
NASDAQ
SCHEDULE 13D/A: ADAR1 Capital Management Urges Keros Therapeutics to Restructure and Return Cash, Vows to Withhold Votes for Directors
ADAR1 Capital Management, Keros Therapeutics' largest shareholder, has publicly outlined proposals to maximize shareholder value, including business restructuring, cash returns, and optimizing the Takeda partnership, while announcing its intent to withhold votes for two current directors.
NASDAQ
SCHEDULE 13D/A: ADAR1 Capital Management Issues Ultimatum to Keros Therapeutics, Demands Strategic Overhaul and Board Changes
ADAR1 Capital Management, Keros Therapeutics' largest shareholder, has publicly criticized the company's capital allocation and strategic direction, announcing its intention to withhold votes for two directors and advocating for significant business restructuring.
NASDAQ
SCHEDULE 13D/A: Shareholder Activist ADAR1 Capital Demands Keros Therapeutics Board Waive Nomination Deadline, Citing Fiduciary Breaches
ADAR1 Capital Management, the largest stockholder of Keros Therapeutics, Inc., has sent a letter to the Board of Directors demanding an immediate waiver or amendment of the annual meeting director nomination deadline, citing alleged breaches of fiduciary duties and actions taken to entrench current directors.
NASDAQ
SCHEDULE 13D/A: Pontifax Group to Nominate Directors to Keros Therapeutics Board, Discloses 11.8% Stake
Pontifax Management 4 GP (2015) Ltd. and affiliated funds have entered into a Letter Agreement with Keros Therapeutics, Inc. to nominate three directors to the company's Board at the 2025 Annual Meeting, while disclosing an aggregate beneficial ownership of 11.8% of common stock.
NASDAQ
ADAR1 Capital Management, holding a 13.29% stake in Keros Therapeutics, has filed a Schedule 13D, expressing concerns over the viability of KER-012 and KER-065 and urging the company to explore strategic options including share buybacks, significant workforce reductions, potential sale, or liquidation to maximize shareholder value.